TetraScience Partners with Landmark Bio to Create Unrestricted Scientific Data Innovation for Next-Generation Genomic Medicines
BOSTON, Mass., May 4, 2023 - TetraScience, Inc., The Scientific Data Cloud Company, announced today that Landmark Bio PBLLC has selected them to accelerate and industrialize next-generation genomic medicines through the Tetra Scientific Data Cloud™.
“We’re thrilled to work with Landmark Bio, who will use the Tetra Scientific Data Cloud to advance their digital strategy,” said Chad Garrett, Chief Revenue Officer, TetraScience. “We’re honored to bring the full weight of our offering to Landmark Bio through our Tetra Data Platform (TDP), Tetra Partner Network (TPN), and our world-leading implementation teams. The TPN has already contributed by bringing an established partnership with a lab informatics partner to this project. Our co-development helped ensure a smooth onboarding process and an optimal user experience.”
Landmark Bio is committed to building a fully digitally integrated biomanufacturing facility, and partnering with TetraScience is an important step in achieving that goal. TetraScience will help the company collect better data, ensure data integrity, and make that data available for subsequent use.
Landmark Bio’s mission is to translate groundbreaking research into life-changing therapies. The company provides therapeutic development expertise, novel manufacturing technologies, in-house quality control, and best-in-class development, regulatory, and supply management practices to their customers.
“Working with TetraScience has had an immediate impact on our digital strategy,” said Shanti Chari, Associate Vice President of Digital Technology and Innovation, Landmark Bio. “TetraScience’s expertise has helped us streamline our data management processes, empowering our teams to focus on data-driven insights and innovation. In the long term, this will help our clients develop safer, more effective therapies and get them to patients quicker.”
The Tetra Scientific Data Cloud combines leading technologies, an extensive ecosystem of life sciences partners, and deep scientific and technology expertise to help life sciences organizations unlock the full value of their scientific data across R&D, manufacturing, and QA/QC.
“Our engagement with TetraScience has been very productive and the team assigned to us is very knowledgeable, proactive, and great to work with,” said Gary Woo, Senior Director of Digital Platforms at Landmark Bio. “Their prior experience with lab work is an asset when interfacing with our scientists and helps guide the system’s deployment and configuration. We are looking forward to our continued partnership as we deploy and expand our TDP footprint.”
“Starting as a facility with a cloud-native IT environment, and operating without a legacy footprint, will allow Landmark Bio to fully capitalize on their wealth of data and expertise quickly and cost-effectively,” said Patrick Grady, TetraScience Chairman and CEO. “We are proud to partner with forward thinkers and innovators who recognize the industry’s inevitable migration to data-centric solutions and dedicate themselves to accelerating and improving scientific outcomes.”
TetraScience is The Scientific Data Cloud company with a mission to accelerate scientific innovation and improve and extend human life. The Tetra Scientific Data Cloud™ is the only open, cloud-native platform purpose-built for science. It connects lab instruments, informatics software, and data apps across the biopharma value chain and delivers the foundation of harmonized, actionable scientific data necessary to transform raw data into accelerated and improved scientific outcomes. For more information, please visit tetrascience.com.
About Landmark Bio
Landmark Bio PBLLC, a statutory public benefit limited liability company, or PBLLC, is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate the development and industrialization of novel therapeutics. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information, visit http://landmarkbio.com.
VP of Product Marketing, TetraScience